Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma (ES)

Protocol applies to the examination of specimens from patients (pediatric and adult) with osseous and extraosseous peripheral PNET / ES.

Protocol date: January 2005
Based on AJCC/UICC TNM, 6th edition

Procedures
• Cytology (No Accompanying Checklist)
• Biopsy (Needle, Incisional, Excisional) (No Accompanying Checklist)
• Resection

Authors
David F. Carpentieri, MD
Department of Pathology, Phoenix Children’s Hospital, Phoenix, Arizona
Stephen J. Qualman, MD
Department of Laboratory Medicine, Children’s Hospital, Columbus, Ohio
Jay Bowen, MS
Department of Laboratory Medicine, Children’s Hospital, Columbus, Ohio
Thomas Krausz, MD
Department of Pathology, University of Chicago Hospitals, Chicago, Illinois
Alberto Marchevsky, MD
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California
Paul S. Dickman, MD
Department of Pathology, Phoenix Children’s Hospital, Phoenix, Arizona
For the Members of the Cancer Committee, College of American Pathologists
Summary

Protocol date: January 2005

This is a new protocol for 2005.

Important Note
Peripheral primitive neuroectodermal tumor (PNET) / Ewing sarcoma (ES) occurs in both children and adults. The malignancy may occur in both bone and soft tissue sites (including unusual sites such as skin or leptomeninges). Because PNET / ES can occur in both bone and soft tissue, AJCC/UICC staging systems for both are included.

First priority should always be given to formalin-fixed tissues for morphologic evaluation. Special studies (eg, reverse transcriptase polymerase chain reaction [RT-PCR]) are critical to the molecular work-up of PNET / ES and require at least 100 mg of viable snap-frozen tissue as the second priority for work-up (Note A).

This protocol is based on the experience of the Children’s Oncology Group. For more information, contact The Children’s Oncology Group Biopathology Center. Phone: (614) 722-2890 or (800) 347-2486.
Surgical Pathology Cancer Case Summary (Checklist)

Protocol date: January 2005
Protocol applies to PNET / ES only
Based on AJCC/UICC TNM, 6th edition

PRIMITIVE NEUROECTODERMAL TUMOR (PNET) / EWING SARCOMA (ES): Resection

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Resection
___ Amputation (specify type): ____________________________
___ Other (specify): ____________________________
___ Not specified

Tumor Site
Specify site(s): _________________________
___ Not specified

Laterality (as appropriate)
___ Right
___ Left
___ Other (specify): ____________________________
___ Not specified

Tumor Size
Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)
Tumor Extent (check all that apply)
*___ Dermal
*___ Subcutaneous
*___ Subfascial
*___ Intramuscular
*___ Intra-abdominal
*___ Retroperitoneal
*___ Bone
*___ Other (specify): ____________________________
*___ Not specified
*___ Cannot be determined

MICROSCOPIC

Extent of Tumor Involvement
___ Limited to dermis
___ Other (specify): ____________________________
___ Cannot be determined

Pathologic Staging

Primary Tumor (pT)

For Primary Osseous Tumors
___ pTX: Primary tumor cannot be assessed
___ pT0: No evidence of primary tumor
___ pT1: Tumor 8 cm or less in greatest dimension
___ pT2: Tumor more than 8 cm in greatest dimension
___ pT3: Discontinuous tumors in the primary bone site

For Primary Extrasosseous Tumors
___ pTX: Primary tumor cannot be assessed
___ pT0: No evidence of primary tumor
pT1: Tumor 5 cm or less in greatest dimension
___ pT1a: Superficial tumor (exclusively above superficial fascia)
___ pT1b: Deep tumor (exclusively deep to or extends across superficial fascia)
pT2: Tumor more than 5 cm in greatest dimension
___ pT2a: Superficial tumor (exclusively above superficial fascia)
___ pT2b: Deep tumor (exclusively deep to or extends across superficial fascia)
Lymph Nodes (check all that apply)

Regional Lymph Nodes (pN)
___ pNX: Cannot be assessed
___ pN0: No regional lymph node involvement
___ pN1: Regional lymph node involvement
Specify:
   Number examined ___
   Number involved ___

Nonregional Lymph Nodes
___ Cannot be assessed
___ No nonregional lymph node involvement
___ Nonregional lymph node involvement
Specify:
   Number examined ___
   Number involved ___

Distant Metastasis (pM)

For Primary Osseous Tumors
___ pMX: Cannot be assessed
___ pM1: Distant metastasis
    ___ pM1a: Lung
    ___ pM1b: Other distant sites
    *Specify site(s): ____________________________

For Primary Extraosseous Tumors
___ pMX: Cannot be assessed
___ pM1: Distant metastasis

Necrosis Postchemotherapy
___ Absent
___ Present
    *Specify extent: ___%
___ Cannot be determined

Margins
___ Cannot be assessed
___ Margins uninvolved by tumor
   Distance of tumor from closest bone margin: ___ mm
   Distance of tumor from closest soft tissue margin: ___ mm
___ Margin(s) involved by tumor
   Specify margin(s): ____________________________

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
*Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)
* ___ Present
* ___ Absent
* ___ Indeterminate

*Additional Studies
*Specify: ____________________________

*Additional Pathologic Findings
*Specify: ____________________________

*Comment(s)